Boryung’s plan to launch a generic version of the liver cancer drug Lenvima (lenvatinib) early to coincide with the expiration of Lenvima’s product patent is facing setbacks. Despite the amount of time spent overcoming the patents, the number of remaining patents seems to be increasing rather than decreasing.

With less than a year left before the expiration of the product patent, Boryung has been unable to overcome all the remaining patents. Rather, the original company filed appeals for some of the first-instance decisions that Boryung won, signaling a prolonged dispute. In addition, Boryung recently discovered an unlisted use patent and filed claims to both invalidate and evade the patent.